Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 55% below its 3-year average of 0.02, near the high end of its 3-year range (-0.31–0.03).
As of the fiscal period ended Tuesday, June 30, 2026. 59.79% below its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
0.02
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-59.79%
CURRENT VS 3Y AVG
-59.44%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 480 covered companies
CURRENT VS SECTOR MEDIAN
-94.60%
vs the sector median at left
Market Cap
$237.08M
Debt to Equity Ratio
N/A
TTM Avg
5.55
3Y Avg
2.78
5Y Avg
1.85
Market Cap
$239.23M
Debt to Equity Ratio
2.16
TTM Avg
6.63
3Y Avg
12.85
5Y Avg
7.19
Market Cap
$231.58M
Debt to Equity Ratio
0.06
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$244.11M
Debt to Equity Ratio
N/A
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
1.23
Market Cap
$244.37M
Debt to Equity Ratio
9.64
TTM Avg
54.87
3Y Avg
37.52
5Y Avg
22.91
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $236.82M | 0.01 | 0.02 | 0.02 | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $237.08M | N/A | 5.55 | 2.78 | 1.85 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.23M | 2.16 | 6.63 | 12.85 | 7.19 |
| High Tide Inc. (HITI)vs › | $241.20M | 1.17 | 1.11 | 0.80 | 1.37 |
| Biodesix, Inc. (BDSX)vs › | $241.33M | 7.85 | 8.11 | 4.57 | 3.79 |
| Keros Therapeutics, Inc. (KROS)vs › | $231.58M | 0.06 | 0.04 | 0.04 | 0.03 |
| Alector, Inc. (ALEC)vs › | $231.49M | N/A | 0.76 | 0.50 | 0.39 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $244.11M | N/A | 0.09 | 0.09 | 1.23 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $244.37M | 9.64 | 54.87 | 37.52 | 22.91 |
| InflaRx N.V. (IFRX)vs › | $244.51M | 0.01 | 0.01 | 0.01 | 0.01 |
Debt/Equity
0.01
Current Ratio
17.19
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.01 |
| 2025-12-31 | 0.02 |
| 2025-09-30 | 0.03 |
| 2025-06-30 | 0.03 |
| 2025-03-31 | 0.03 |
| 2024-12-31 | 0.03 |
| 2024-09-30 | 0.03 |
| 2024-06-30 | -0.06 |
| 2024-03-31 | -0.07 |
| 2023-12-31 | -0.31 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
